NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.44 -0.04 (-1.61 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$2.44
Today's Range$2.35 - $2.65
52-Week Range$0.93 - $2.88
Volume730,836 shs
Average Volume230,896 shs
Market Capitalization$133.99 million
P/E Ratio-4.69
Dividend YieldN/A
Beta0.92
Eyepoint Pharmaceuticals logoEyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Debt-to-Equity Ratio1.57
Current Ratio0.83
Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio-4.69
Forward P/E Ratio-5.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.54 million
Price / Sales17.48
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book7.18

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-18,480,000.00
Net Margins-843.54%
Return on Equity-246.01%
Return on Assets-103.22%

Miscellaneous

Employees22
Outstanding Shares54,030,000
Market Cap$133.99

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business had revenue of $0.93 million for the quarter, compared to analysts' expectations of $0.69 million. Eyepoint Pharmaceuticals had a negative net margin of 843.54% and a negative return on equity of 246.01%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Eyepoint Pharmaceuticals.

What price target have analysts set for EYPT?

4 Wall Street analysts have issued twelve-month price targets for Eyepoint Pharmaceuticals' stock. Their forecasts range from $2.50 to $10.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $5.6250 in the next twelve months. This suggests a possible upside of 130.5% from the stock's current price. View Analyst Ratings for Eyepoint Pharmaceuticals.

What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (7/10/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks. Our price target is derived from a market value of $245M for EyePoint, which includes a discounted cash flow-based asset value of $265M that includes DEXYCU, YUTIQ, and royalties from 15% discount rate and 2% terminal growth rate. Probability of success assigned to YUTIQ is 90%." (6/26/2018)

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a decline in short interest in June. As of June 29th, there was short interest totalling 948,858 shares, a decline of 31.4% from the June 15th total of 1,383,652 shares. Based on an average trading volume of 270,517 shares, the days-to-cover ratio is presently 3.5 days. Currently, 3.6% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Who are some of Eyepoint Pharmaceuticals' key competitors?

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
  • Mr. Leonard S. Ross, VP of Fin., Chief Accounting Officer & Principal Financial Officer (Age 68)
  • Dr. Dario A. Paggiarino M.D., VP & Chief Medical Officer (Age 61)
  • Mr. Marty Nazzaro, Sr. VP of Operations
  • Dr. Anna Kluczewska B.D.Sc., CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Media stories about EYPT stock have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyepoint Pharmaceuticals earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media coverage about the company an impact score of 46.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (0.15%) and Creative Planning (0.14%). Company insiders that own Eyepoint Pharmaceuticals stock include Ew Healthcare Partners, LP and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

Which major investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Creative Planning. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Ew Healthcare Partners, LP and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $2.44.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $133.99 million and generates $7.54 million in revenue each year. The company earns $-18,480,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Eyepoint Pharmaceuticals employs 22 workers across the globe.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]


MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.